Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
MEKINIST
NDA
Get alerts
TRAMETINIB DIMETHYL SULFOXIDE | N217513 | NOVARTIS PHARMACEUTICALS CORP
1 strength
2 unique patents
3 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
2 unique patents, 2 exclusivities by expiration date
Expiring < 1yr (1)
Active (1)
Today
PED (+6 mo)
Exclusivity
2026
2027
2028
2029
2030
2031
Today
7378423
Nov. 29, 2027
8703781
Apr. 15, 2031
NP
Sep. 16, 2030
ODE-428
Sep. 16, 2030
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 0.05MG BASE/ML
RLD
2 patents
3 exclusivities
▴
SOLUTION;ORAL | Approved: Mar 16, 2023
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7378423
May 29, 2027
PED: Nov 29, 2027
PED
Yes
Yes
—
—
8703781
Oct 15, 2030
PED: Apr 15, 2031
PED
Yes
Yes
U-3564
MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
—
Exclusivities (3)
Code
Date
Status
NP
Mar 16, 2026
Expired
ODE-428
Mar 16, 2030
Active
PED
Sep 16, 2030
Active